Autopsy report · NCT05147350

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

“Sponsor decided to terminate the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 6 months before it stopped.
• 38 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Debiopharm International SA

Sponsor type

Industry

Conditions

Advanced Solid Tumor

Interventions

RP-6306 (oral PKMYT1 inhibitor)

Participants

38

Sites

9

Countries

Canada, Spain, United Kingdom, United States

Trials that died the same way

• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (97% match in meaning)
• An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
  “The sponsor decided to terminate the study early” (95% match in meaning)
• Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
  “The Sponsor terminated the study.” (94% match in meaning)
• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
  “Sponsor decision to terminate study.” (94% match in meaning)
• Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
  “Study terminated by the Sponsor” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.